Compare MakeMyTrip Ltd (MMYT) vs TransMedics Group Inc (TMDX) Price & Performance

MakeMyTrip (MMYT) trades at $53.22, down 2.56% on the day, with a bullish technical signal despite recent weakness. The company shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.25 beating expectations of $0.17. Revenue reached $978.34 million in 2025 with a 73.77% gross margin, though 2026 projections indicate margin compression. Analyst sentiment remains positive with 73% buy ratings and a 34% upside target.

The stock presents a growth opportunity with strong operational performance but faces risks from travel disruptions and rising debt levels. While current valuation metrics appear elevated (P/E 147.78), the company's market leadership in Indian online travel and consistent execution support the bullish case. Key risks include competitive pressures and macroeconomic sensitivity to travel demand.

TransMedics (TMDX) is trading at $73.47, down 0.69% on the day, amid a mixed technical and fundamental backdrop. The stock shows neutral technical signals with support near $72 and resistance at $75, while fundamentals are strong with a trailing P/E of 16.81 and robust profitability metrics like a 27.04% net income margin. Recent earnings saw a Q1 2026 miss but beats in prior quarters, and the company is expanding in Europe through strategic investments.

The outlook is cautiously optimistic with a consensus price target of $108.71 implying significant upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion costs and competitive threats, but the company's organ transplant logistics network offers a durable competitive advantage for long-term growth.